Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-848d4c4894-pftt2 Total loading time: 0 Render date: 2024-04-30T11:02:56.728Z Has data issue: false hasContentIssue false

Chapter 14 - Drugs to Treat Dementia

from Part 2 - Psychopharmacology of the Main Psychotropic Drug Groups

Published online by Cambridge University Press:  29 May 2020

By
Ross Dunne  and
Alistair Burns
Edited by
Peter M. Haddad  and
David J. Nutt
Peter M. Haddad
Affiliation:
Hamad Medical Corporation, Qatar
David J. Nutt
Affiliation:
Centre for Neuropsychopharmacology, Division of Psychiatry, Department of Brain Sciences, Imperial College London
Get access

Summary

Dementia is a clinical syndrome that is estimated to affect 46 million people worldwide. This number is estimated to increase to 131.5 million by 2050 (Prince et al., 2015). Dementia has a huge impact on people with the condition, their families and on health and social services. In the UK alone, it affects some 850 000 people with an estimated annual cost of £26 billion. It is a progressive neuropsychiatric condition leading to a significant strain on individuals, their families and the wider society. The risk increases with age and the burden of disease is set to rise in the coming years (Prince et al., 2015). While symptomatic treatments for the commonest cause of dementia, Alzheimer’s disease, are available, no disease-modifying therapy has emerged and the majority of trials in this space have been negative although there is room for optimism (Aisen, 2017).

Type
Chapter
Information
Seminars in Clinical Psychopharmacology , pp. 433 - 453
Publisher: Cambridge University Press
Print publication year: 2020

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Aisen, P (2017). Continuing progress in Alzheimer’s disease trials. J Prev Alz Dis, 4(4), 211–212.Google Scholar
Auriacombe, S, Pere, J-J, Loria-Kanza, Y, Vellas, B (2002). Efficacy and safety of rivastigmine in patients with Alzheimer’s disease who failed to benefit from treatment with donepezil. Curr Med Res Opin, 18, 129–138. doi:10.1185/030079902125000471.CrossRefGoogle ScholarPubMed
Banerjee, S, Hellier, J, Romeo, R, et al. (2013). Study of the use of antidepressants for depression in dementia: the HTA-SADD trial – a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine. Health Technol Assess, 17, 1–166.Google Scholar
Beck, AT, Rush, A, Shaw, B, Emery, G (1979). Cognitive Therapy of Depression. New York: Guilford Press.Google Scholar
Bickel, U, Thomsen, T, Weber, W, et al. (1991). Pharmacokinetics of galanthamine in humans and corresponding cholinesterase inhibition. Clin Pharmacol Ther, 50, 420–428.Google Scholar
Birks, J, Grimley Evans, J, Iakovidou, V, Tsolaki, M (2009). Rivastigmine for Alzheimer’s disease. Cochrane Database Syst Rev, (2), CD001191. doi:10.1002/14651858.CD001191.pub2.Google Scholar
Bolea-Alamanac, BM, Davies, SJ, Christmas, DM, et al. (2011). Cyproterone to treat aggressivity in dementia: a clinical case and systematic review. J Psychopharmacol, 25(1), 141–145.Google Scholar
Braak, H, Del Tredici, K (2015). Neuroanatomy and pathology of sporadic Alzheimer’s disease. Adv Anat Embryol Cell Biol, 215, 1–162.Google Scholar
Braak, H, Ghebremedhin, E, Rüb, U, Bratzke, H, Del Tredici, K (2004). Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res, 318, 121–134.Google Scholar
Bullock, R, Connolly, C (2002). Switching cholinesterase inhibitor therapy in Alzheimer’s disease: donepezil to rivastigmine, is it worth it? Int J Geriatr Psychiatry, 17, 288–289.CrossRefGoogle ScholarPubMed
Campbell, NL, Perkins, AJ, Gao, S, et al. (2017). Adherence and tolerability of Alzheimer’s disease medications: a pragmatic randomized trial. J Am Geriatr Soc, 65, 1497–1504.Google Scholar
Chen, YD, Zhang, J, Wang, Y, Yuan, JL, Hu, WL (2016). Efficacy of cholinesterase inhibitors in vascular dementia: an updated meta-analysis. Eur Neurol, 75, 132–141.Google Scholar
Chew, ML, Mulsant, BH, Pollock, BG, et al. (2008). Anticholinergic activity of 107 medications commonly used by older adults. J Am Geriatr Soc, 56, 1333–1341.Google Scholar
Collerton, D, Mosimann, UP, Perry, E (2015). The Neuroscience of Visual Hallucinations. Chichester: John Wiley & Sons.Google Scholar
Corbett, A, Burns, A, Ballard, C (2014). Don’t use antipsychotics routinely to treat agitation and aggression in people with dementia. BMJ, 349, g6420.Google Scholar
Cummings, JL, Mega, M, Gray, K, et al. (1994). The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology, 44, 2308–2314.CrossRefGoogle ScholarPubMed
Cummings, JL, Geldmacher, D, Farlow, M, et al. (2013). High-dose donepezil (23 mg/day) for the treatment of moderate and severe Alzheimer’s disease: drug profile and clinical guidelines. CNS Neurosci Ther, 19, 294–301.CrossRefGoogle ScholarPubMed
Cummings, J, Ballard, C, Tariot, P, et al. (2018). Pimavanserin: potential treatment for dementia-related psychosis. J Prev Alzheimers Dis, 5(4), 253–258.Google Scholar
Dawson, GR, Iversen, SD (1993). The effects of novel cholinesterase inhibitors and selective muscarinic receptor agonists in tests of reference and working memory. Behav Brain Res, 57, 143–153.Google Scholar
de Vasconcelos Cunha, UG, Lopes Rocha, F, Ávila de Melo, R, et al. (2007). A placebo-controlled double-blind randomized study of venlafaxine in the treatment of depression in dementia. Dement Geriatr Cogn Disord, 24, 36–41. doi:10.1159/000102570.Google Scholar
Devos, D, Moreau, C, Maltête, D, et al. (2014). Rivastigmine in apathetic but dementia and depression-free patients with Parkinson’s disease: a double-blind, placebo-controlled, randomised clinical trial. J Neurol Neurosurg Psychiatry, 85, 668–674. doi:10.1136/jnnp-2013-306439.Google Scholar
Drui, G, Carnicella, S, Carcenac, C, et al. (2014). Loss of dopaminergic nigrostriatal neurons accounts for the motivational and affective deficits in Parkinson’s disease. Mol Psychiatry, 19, 358–367. doi:10.1038/mp.2013.3.CrossRefGoogle ScholarPubMed
Ecker, D, Unrath, A, Kassubek, J, Sabolek, M (2009). Dopamine agonists and their risk to induce psychotic episodes in Parkinson’s disease: a case-control study. BMC Neurol, 9, 23. doi:10.1186/1471-2377-9-23.CrossRefGoogle ScholarPubMed
Emre, M, Tsolaki, M, Bonucelli, U, et al. (2010). Memantine for patients with Parkinson’s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol, 9(10), 969–977.Google Scholar
Engedal, K, Davis, B, Richarz, U, et al. (2012). Two galantamine titration regimens in patients switched from donepezil. Acta Neurol Scand, 126, 37–44. doi:10.1111/j.1600-0404.2011.01594.x.Google Scholar
Fox, C, Livingston, G, Maidment, ID, et al. (2011). The impact of anticholinergic burden in Alzheimer’s dementia – the laser-AD study. Age Ageing, 40, 730–735.CrossRefGoogle ScholarPubMed
Ghaleiha, A, Ghyasvand, M, Mohammadi, MR, et al. (2014). Galantamine efficacy and tolerability as an augmentative therapy in autistic children: a randomized, double-blind, placebo-controlled trial. J Psychopharmacol, 28, 677–685.Google Scholar
Glasgow, NG, Povysheva, NV, Azofeifa, AM, Johnson, JW (2017). Memantine and ketamine differentially alter NMDA receptor desensitization. J Neurosci, 37, 9686–9704.CrossRefGoogle ScholarPubMed
Gobburu, JVS, Tammara, V, Lesko, L, et al. (2001). Pharmacokinetic-pharmacodynamic modeling of rivastigmine, a cholinesterase inhibitor, in patients with Alzheimer’s disease. J Clin Pharmacol, 41, 1082–1090.Google Scholar
Green, AR, Oh, E, Hilson, L, Tian, J, Boyd, CM (2016). Anticholinergic burden in older adults with mild cognitive impairment. J Am Geriatr Soc, 64, e313–e314.Google Scholar
Grossberg, GT, Manes, F, Allegri, RF, et al. (2013). The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer’s disease taking cholinesterase inhibitors. CNS Drugs, 27, 469–478.Google Scholar
Haddad, PM, Benbow, SM (1993a). Sexual problems associated with dementia: Part 1. Problems and their consequences. Int J Geriatr Psychiatry, 8(7), 547–551.CrossRefGoogle Scholar
Haddad, PM, Benbow, SM (1993b). Sexual problems associated with dementia: Part 2. Aetiology, assessment and treatment. Int J Geriatr Psychiatry, 8(8), 631–637.Google Scholar
Herrmann, N, Mamdani, M, Lanctôt, KL (2004). Atypical antipsychotics and risk of cerebrovascular accidents. Am J Psychiatry, 161, 1113–1115. doi:10.1176/appi.ajp.161.6.1113.Google Scholar
Hilmas, CJ, Poole, MJ, Finneran, K, Clark, MG, Williams, PT (2009). Galantamine is a novel post-exposure therapeutic against lethal VX challenge. Toxicol Appl Pharmacol, 240, 166–173.CrossRefGoogle ScholarPubMed
Hinkle, JT, Perepezko, K, Bakker, C, et al. (2018). Onset and remission of psychosis in Parkinson’s disease: pharmacologic and motoric markers. Mov Disord Clin Pract, 5, 31–38. doi:10.1002/mdc3.12550.Google Scholar
Holroyd, S, Currie, L, Wooten, GF (2001). Prospective study of hallucinations and delusions in Parkinson’s disease. J Neurol Neurosurg Psychiatry, 70, 734–738. doi:10.1136/jnnp.70.6.734.Google Scholar
Hong, JM, Shin, DH, Lim, TS, Lee, JS, Huh, K (2012). Galantamine administration in chronic post-stroke aphasia. J Neurol Neurosurg Psychiatry, 83, 675–680. doi:10.1136/jnnp-2012-302268.Google Scholar
Howard, R, McShane, R, Lindesay, J, et al. (2012). Donepezil and memantine for moderate-to-severe Alzheimer’s disease. N Engl J Med, 366, 893–903.Google Scholar
Howard, R, McShane, R, Lindesay, J, et al. (2015). Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer’s Disease (DOMINO-AD) trial: secondary and post-hoc analyses. Lancet Neurol, 14, 1171–1181.Google Scholar
Huang, F, Lasseter, AC, Janssens, L, et al. (2002). Pharmacokinetic and safety assessments of galantamine and risperidone after the two drugs are administered alone and together. J Clin Pharmacol, 42, 1341–1351.CrossRefGoogle ScholarPubMed
Irwin, DJ, Grossman, M, Weintraub, D, et al. (2017). Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. Lancet Neurol, 16, 55–65.CrossRefGoogle ScholarPubMed
Jang, YK, Lyoo, CH, Park, S, et al. (2018). Head to head comparison of [18F] AV-1451 and [18F] THK5351 for tau imaging in Alzheimer’s disease and frontotemporal dementia. Eur J Nucl Med Mol Imaging, 45, 432–442.Google Scholar
Jann, MW, Shirley, KL, Small, GW (2002). Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet, 41, 719–739.Google Scholar
Jiang, J, Jiang, H (2015). Efficacy and adverse effects of memantine treatment for Alzheimer’s disease from randomized controlled trials. Neurol Sci, 36, 1633–1641.Google Scholar
Johansson, I, Nordberg, A (1993). Pharmacokinetic studies of cholinesterase inhibitors. Acta Neurol Scand Suppl, 149, 22–25.Google Scholar
Kavirajan, H, Schneider, LS (2007). Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol, 6, 782–792. doi:10.1016/S1474-4422(07)70195-3.Google Scholar
Kishi, T, Matsunaga, S, Iwata, N (2015). Memantine for the treatment of frontotemporal dementia: a meta-analysis. Neuropsychiatr Dis Treat, 11, 2883–2885.Google Scholar
Kobayashi, H, Ohnishi, T, Nakagawa, R, Yoshizawa, K (2016). The comparative efficacy and safety of cholinesterase inhibitors in patients with mild-to-moderate Alzheimer’s disease: a Bayesian network meta-analysis. Int J Geriatr Psychiatry, 31, 892–904.Google Scholar
Larsson, V, Aarsland, D, Ballard, C, Minthon, L, Londos, E (2010). The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson’s disease dementia. Int J Geriatr Psychiatry, 25, 1030–1038. doi:10.1002/gps.2506.Google Scholar
Lefèvre, G, Callegari, F, Gsteiger, S, Xiong, Y (2016). Effects of renal impairment on steady-state plasma concentrations of rivastigmine: a population pharmacokinetic analysis of capsule and patch formulations in patients with Alzheimer’s disease. Drugs Aging, 33, 725–736.Google Scholar
Liu, AKL, Chang, RCC, Pearce, RKB, Gentleman, SM (2015). Nucleus basalis of Meynert revisited: anatomy, history and differential involvement in Alzheimer’s and Parkinson’s disease. Acta Neuropathol, 129, 527–540. doi:10.1007/s00401-015-1392-5.Google Scholar
Livingston, G, Kelly, J, Lewis-Holmes, E, et al. (2014). A systematic review of the clinical effectiveness and cost-effectiveness of sensory, psychological and behavioural interventions for managing agitation in older adults with dementia. Health Technol Assess, 18, 1–226, v–vi.Google Scholar
López-Valdés, HE, Clarkson, AN, Ao, Y, et al. (2014). Memantine enhances recovery from stroke. Stroke, 45, 2093–2100. doi:10.1161/STROKEAHA.113.004476.Google Scholar
Massoud, F, Desmarais, JE, Gauthier, S (2011). Switching cholinesterase inhibitors in older adults with dementia. Int Psychogeriatr, 23, 372–378. doi:10.1017/S1041610210001985.CrossRefGoogle ScholarPubMed
Matsunaga, S, Kishi, T, Iwata, N (2015a). Memantine monotherapy for Alzheimer’s disease: a systematic review and meta-analysis. PLoS One, 10(4), e0123289. doi:10.1371/journal.pone.0123289.Google Scholar
Matsunaga, S, Kishi, T, Iwata, N (2015b). Combination therapy with cholinesterase inhibitors and memantine for Alzheimer’s disease: a systematic review and meta-analysis. Int J Neuropsychopharmacol, 18, pyu115. doi:10.1093/ijnp/pyu115.CrossRefGoogle Scholar
Meltzer, HY, Mills, R, Revell, S, et al. (2010). Pimavanserin, a serotonin 2 A receptor inverse agonist, for the treatment of Parkinson’s disease psychosis. Neuropsychopharmacology, 35, 881–892.Google Scholar
National Institute for Health and Care Excellence (NICE) (2018a). Decision aid: antipsychotic medicines for treating agitation, aggression and distress in people living with dementia. London: National Institute for Health and Care Excellence. Available at: www.nice.org.uk/guidance/ng97/resources/antipsychotic-medicines-for-treating-agitation-aggression-and-distress-in-people-living-with-dementia-patient-decision-aid-pdf-4852697005 (last accessed 26.1.19).Google Scholar
National Institute for Health and Care Excellence (NICE) (2018b). Dementia: assessment, management and support for people living with dementia and their carers. NICE guideline [NG97]. London: National Institute for Health and Care Excellence.Google Scholar
Nelson, JC, Devanand, DP (2011). A systematic review and meta-analysis of placebo-controlled antidepressant studies in people with depression and dementia. J Am Geriatr Soc, 59, 577–585. doi:10.1111/j.1532-5415.2011.03355.x.Google Scholar
Noetzli, M, Guidi, M, Ebbing, K, et al. (2013). Population pharmacokinetic study of memantine: effects of clinical and genetic factors. Clin Pharmacokinet, 52, 211–223.Google Scholar
Ohnishi, A, Mihara, M, Kamakura, H, et al. (1993). Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer’s disease, in healthy young and elderly subjects. J Clin Pharmacol, 33, 1086–1091.Google Scholar
Ohta, Y, Darwish, M, Hishikawa, N, et al. (2017). Therapeutic effects of drug switching between acetylcholinesterase inhibitors in patients with Alzheimer’s disease. Geriatr Gerontol Int, 17, 1843–1848. doi:10.1111/ggi.12971.CrossRefGoogle ScholarPubMed
Pagonabarraga, J, Kulisevsky, J, Strafella, AP, Krack, P (2015). Apathy in Parkinson’s disease: clinical features, neural substrates, diagnosis, and treatment. Lancet Neurology, 14, 518–531. doi:10.1016/S1474-4422(15)00019-8.Google Scholar
Pasina, L, Djade, CD, Lucca, U, et al. (2013). Association of anticholinergic burden with cognitive and functional status in a cohort of hospitalized elderly: comparison of the anticholinergic cognitive burden scale and anticholinergic risk scale: results from the REPOSI study. Drugs Aging, 30, 103–112.Google Scholar
Pereira, EFR, Aracava, Y, Alkondon, M, et al. (2010). Molecular and cellular actions of galantamine: clinical implications for treatment of organophosphorus poisoning. J Mol Neurosci, 40, 196–203.Google Scholar
Periclou, A, Ventura, D, Rao, N, Abramowitz, W (2006). Pharmacokinetic study of memantine in healthy and renally impaired subjects. Clin Pharmacol Ther, 79, 134–143.Google Scholar
Perry, EK, Curtis, M, Dick, DJ, et al. (1985). Cholinergic correlates of cognitive impairment in Parkinson’s disease: comparisons with Alzheimer’s disease. J Neurol Neurosurg Psychiatry, 48, 413–421.Google Scholar
Piotrovsky, V, Van Peer, A, Van Osselaer, N, Armstrong, M, Aerssens, J (2003). Galantamine population pharmacokinetics in patients with Alzheimer’s disease: modeling and simulations. J Clin Pharmacol, 43, 514–523.Google Scholar
Polinsky, RJ (1998). Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease. Clin Ther, 20, 634–647.CrossRefGoogle ScholarPubMed
Prince, M, Wimo, A, Guerchet, M, et al. (2015). World Alzheimer Report 2015 – The Global Impact of Dementia: An Analysis of Prevalence, Incidence, Cost and Trends. London: Alzheimer’s Disease International. Available at: www.alz.co.uk/research/WorldAlzheimerReport2015.pdf (last accessed 10.8.19).Google Scholar
Risacher, SL, McDonald, BC, Tallman, EF, et al. (2016). Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults. JAMA Neurol, 73, 721–732.Google Scholar
Ruxton, K, Woodman, RJ, Mangoni, AA (2015). Drugs with anticholinergic effects and cognitive impairment, falls and all-cause mortality in older adults: a systematic review and meta-analysis. Br J Clin Pharmacol, 80, 209–220.Google Scholar
Sabbagh, M, Hans, S, Kim, S, et al. (2016). Clinical recommendations for the use of donepezil 23 mg in moderate-to-severe Alzheimer’s disease in the Asia-Pacific region. Dement Geriatr Cogn Dis Extra, 6, 382–395.Google Scholar
Salahudeen, MS, Duffull, SB, Nishtala, PS (2015). Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review. BMC Geriatr, 15, 31.Google Scholar
Sasaki, S, Horie, Y (2014). The effects of an uninterrupted switch from donepezil to galantamine without dose titration on behavioral and psychological symptoms of dementia in Alzheimer’s disease. Dement Geriatr Cogn Dis Extra, 4, 131–139. doi:10.1159/000362871.Google Scholar
Schmidt, R, Hofer, E, Bouwman, FH, et al. (2015). EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer’s disease. Eur J Neurol, 22, 889–898.Google Scholar
Schneider-Thoma, J, Efthimiou, O, Huhn, M, et al. (2018). Second-generation antipsychotic drugs and short-term mortality: a systematic review and meta-analysis of placebo-controlled randomised controlled trials. Lancet Psychiatry, 5, 653–663.CrossRefGoogle ScholarPubMed
Serfaty, M, Kennell-Webb, S, Warner, J, Blizard, R, Raven, P (2002). Double blind randomised placebo controlled trial of low dose melatonin for sleep disorders in dementia. Int J Geriatr Psychiatry, 17, 1120–1127.Google Scholar
Sharp, SI, Francis, PT, Elliot, MSJ, et al. (2009). Choline acetyltransferase activity in vascular dementia and stroke. Dement Geriatr Cogn Disord, 28, 233–238. doi:10.1159/000239235.Google Scholar
Sullivan, SC, Richards, KC (2004). Predictors or circadian sleep-wake rhythm maintenance in elders with dementia. Aging Ment Health, 8, 143–152. doi:10.1080/13607860410001649608.Google Scholar
Tariot, PN, Farlow, MR, Grossberg, GT, et al. (2004). Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil. JAMA, 291, 317–324.Google Scholar
Thobois, S, Lhommée, E, Klinger, H, et al. (2013). Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil. Brain, 136, 1568–1577.Google Scholar
Trotman, M, Vermehren, P, Gibson, CL, Fern, R (2015). The dichotomy of memantine treatment for ischemic stroke: dose-dependent protective and detrimental effects. J Cereb Blood Flow Metab, 35, 230–239. doi:10.1038/jcbfm.2014.188.Google Scholar
van Gool, WA, van de Beek, D, Eikelenboom, P (2010). Systemic infection and delirium: when cytokines and acetylcholine collide. Lancet, 375(9716), 773–775. doi:10.1016/S0140-6736(09)61158-2.Google Scholar
Van Leeuwen, E, Petrovic, M, Azermai, M, et al. (2018). Withdrawal versus continuation of long-term antipsychotic drug use for behavioural and psychological symptoms in older people with dementia. Cochrane Database Syst Rev, (3), CD007726.Google Scholar
Vingtdeux, V, Dreses-Werringloer, U, Zhao, H, Davies, P, Marambaud, P (2008). Therapeutic potential of resveratrol in Alzheimer’s disease. BMC Neurosci, 9, S6.Google Scholar
Wang, J, Yu, JT, Wang, HF, et al. (2015). Pharmacological treatment of neuropsychiatric symptoms in Alzheimer’s disease: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry, 86, 101–109.Google Scholar
Weintraub, D, Chiang, C, Kim, HM, et al. (2016). Association of antipsychotic use with mortality risk in patients with Parkinson disease. JAMA Neurol, 73, 535–541. doi:10.1001/jamaneurol.2016.0031.Google Scholar
Wesnes, K, Aarsland, D, Ballard, C, Londos, E (2014). Memantine improves attention and episodic memory in Parkinson’s disease dementia and dementia with Lewy bodies. Int J Geriatr Psychiatry, 30(1), 46–54.Google Scholar
Zhang, L-J, Sha, X-Y (2007). Pharmacokinetics and bioequivalence studies of galantamine hydrobromide dispersible tablet in healthy male Chinese volunteers. Drug Dev Ind Pharm, 33, 335–340.Google Scholar
Zhao, Q, Janssens, L, Verhaeghe, T, Brashear, HR, Truyen, L (2005). Pharmacokinetics of extended-release and immediate-release formulations of galantamine at steady state in healthy volunteers. Curr Med Res Opin, 21, 1547–1554.Google Scholar
Zhao, QF, Tan, L, Wang, HF, et al. (2016). The prevalence of neuropsychiatric symptoms in Alzheimer’s disease: systematic review and meta-analysis. J Affect Disord, 190, 264–271.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×